跳至主要内容
临床试验/CTRI/2019/08/020965
CTRI/2019/08/020965招募中未知

Effects of Maintaining Steady Albumin Levels by Targeted Albumin Therapy (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites and Low Serum Albumin Level- a Randomized Controlled Trial

Institute of Liver and Biliary Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Newly detected cirrhotic patients aged more than 18 years
  • 2) Cirrhosis deï¬?ned by standard clinical, analytical and/or histological criteria
  • 3) Serum albumin level < 2.8g/dl with or without ascites
  • 4) Who would agree to give written informed consent

排除标准

  • 1.Uncontrolled HTN (sys >150/ dis >90 mmHg) or h/o any drug therapy for HTN
  • 2.Prior h/o Transjugular Intrahepatic Portosystemic Shunt (TIPS)
  • 3.Hepatocellular Carcinoma
  • 4.Active alcohol abuse within 3 months
  • 5.Patients presenting as Acute on Chronic Liver Failure
  • 6.Extrahepatic organ failure
  • 7.Known case of chronic heart failure or respiratory failure
  • 8.Diagnosed Chronic Kidney Disease
  • 9.Patients with hydrothorax
  • 10.Prior liver transplant recipient
  • 11.Human Immunodeficiency Virus infection
  • 12.Use of albumin infusion in the last one month
  • 13.CTP >12, MELD >28
  • 14.Total Bilirubin >3 g/dl
  • 15.Overt Hepatic Encephalopathy at Presentation

研究者

相似试验